BridgeBio Pharma, Inc. — Director's Dealing 2025

Sep 9, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BridgeBio Pharma, Inc. (BBIO)
CIK: 0001743881
Period of Report: 2025-09-04

Reporting Person: Kumar Neil (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-09-04	Common Stock	S	14525	$51.1504	Disposed	4703922	Indirect
2025-09-04	Common Stock	S	5475	$51.8543	Disposed	4698447	Indirect
2025-09-05	Common Stock	S	2300	$51.9546	Disposed	4696147	Indirect
2025-09-05	Common Stock	S	16800	$53.1622	Disposed	4679347	Indirect
2025-09-05	Common Stock	S	900	$53.8044	Disposed	4678447	Indirect
2025-09-04	Common Stock	S	14558	$51.1567	Disposed	901128	Indirect
2025-09-04	Common Stock	S	5442	$51.8535	Disposed	895686	Indirect
2025-09-05	Common Stock	S	2300	$51.9625	Disposed	893386	Indirect
2025-09-05	Common Stock	S	16900	$53.1627	Disposed	876486	Indirect
2025-09-05	Common Stock	S	800	$53.7994	Disposed	875686	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	223090	Direct

Footnotes

F1: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025.

F2: Represents the weighted average sale price of the shares sold from $50.53 to $51.52 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

F3: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.

F4: Represents the weighted average sale price of the shares sold from $51.53 to $52.35 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

F5: Represents the weighted average sale price of the shares sold from $51.58 to $52.56 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

F6: Represents the weighted average sale price of the shares sold from $52.65 to $53.62 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

F7: Represents the weighted average sale price of the shares sold from $53.70 to $53.90 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

F8: Represents the weighted average sale price of the shares sold from $50.52 to $51.49 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

F9: Represents the weighted average sale price of the shares sold from $51.52 to $52.35 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

F10: Represents the weighted average sale price of the shares sold from $51.64 to $52.56 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

F11: Represents the weighted average sale price of the shares sold from $53.66 to $53.91 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.